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Abstract
Background: Host genetic factors might affect the risk of progression from infection with carcinogenic human
papillomavirus (HPV), the etiologic agent for cervical cancer, to persistent HPV infection, and hence to cervical precancer
and cancer.
Methodology/Principal Findings: We assessed 18,310 tag single nucleotide polymorphisms (SNPs) from 1113 genes in 416
cervical intraepithelial neoplasia 3 (CIN3)/cancer cases, 356 women with persistent carcinogenic HPV infection (median
persistence of 25 months) and 425 randomly selected women (non-cases and non-HPV persistent) from the 10,049 women
from the Guanacaste, Costa Rica HPV natural history cohort. For gene and SNP associations, we computed age-adjusted
odds ratio and p-trend. Three comparisons were made: 1) association with CIN3/cancer (compared CIN3/cancer cases to
random controls), 2) association with persistence (compared HPV persistence to random controls), and 3) progression
(compared CIN3/cancers with HPV-persistent group). Regions statistically significantly associated with CIN3/cancer included
genes for peroxiredoxin 3 PRDX3, and ribosomal protein S19 RPS19. The single most significant SNPs from each gene
associated with CIN3/cancer were PRDX3 rs7082598 (Ptrend,0.0001), and RPS19 rs2305809 (Ptrend=0.0007), respectively.
Both SNPs were also associated with progression.
Conclusions/Significance: These data suggest involvement of two genes, RSP19 and PRDX3, or other SNPs in linkage
disequilibrium, with cervical cancer risk. Further investigation showed that they may be involved in both the persistence
and progression transition stages. Our results require replication but, if true, suggest a role for ribosomal dysfunction,
mitochondrial processes, and/or oxidative stress, or other unknown function of these genes in cervical carcinogenesis.
Citation: Safaeian M, Hildesheim A, Gonzalez P, Yu K, Porras C, et al. (2012) Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence
and Cervical Precancer/Cancer. PLoS ONE 7(4): e33619. doi:10.1371/journal.pone.0033619
Editor: Javier S. Castresana, University of Navarra, Spain
Received October 6, 2011; Accepted February 14, 2012; Published April 9, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The study was funded by intramural NCI and the NIH Office of Research On Women’s Health. The authors are grateful to Sabrina Chen from the
Information Management Services, Inc. (IMS) for data management and programming support. They are also grateful to Amy Hutchinson and Belynda Hicks for
their management of this genotyping effort at the NCI Core Genotyping Facility and for their scientific contributions to the authors’ research efforts. Q. Li is
partially supported by National Young Science Foundation of China No. 10901155. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: Laurie Burdette and Stephen J. Chanock are employed by The Core Genotyping Facility (CGF) which is within the Division of Cancer
Epidemiology and Genetics (DCEG) of the National Cancer Institute (NCI) and supported by SAIC-Frederick Inc. Information Management Services, Inc. also
supported this study, along with Amy Hutchinson and Belynda Hicks with their management of this genotyping effort at the NCI Core Genotyping Facility and
for their scientific contributions to the authors’ research efforts. This does not alter the authors’ adherence to all PloS ONE policies on sharing data and
materials.
* E-mail: safaeianm@mail.nih.gov
Introduction
While it is well-known that carcinogenic human papillomavi-
ruses (HPVs) are the causal agents of cervical cancer, HPV
infections are extremely common relative to rare cancer incidence,
indicating that many infections spontaneously resolve [1], or
persist without progression. Host genetic factors may play a role in
cervical carcinogenesis and are thought to influence who develops
persistent HPV infection and perhaps who further progresses to
cancer [2–7].
The role of host genetic factors and other co-factors associated
with cervical cancer are particularly interesting because the
stepwise pathogenesis of the disease has been extensively studied.
From its initiation through HPV infection at the cervical
transformation zone, and subsequent steps related to viral
persistence, progression to precancer, and invasion [1], the same
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33619or different factors can be associated with each step towards
pathogenesis. The role of non-genetic co-factors in persistence and
progression has been well-studied, but there are fewer studies on
the host genetics role on the pathogenesis of cervical cancer. Thus,
genetic studies of cervical cancer supplement comparisons of
cancer cases to non-cancer or uninfected controls, by investigating
each intermediate causal step, namely persistent infection and
progression to CIN3/cancer.
We used data from the well-characterized, longitudinal cohort
study on HPV natural history (NHS) in Guanacaste, Costa Rica,
and recently reported results from a panel of 7,140 candidate
single nucleotide polymorphisms (SNPs). These polymorphisms
were chosen to represent variation in 305 genes based on a priori
hypotheses of association with HPV infection and cervical cancer
(DNA repair, viral infection and cell entry pathways). That effort
identified 8 potential genes associated with cervical cancer,
including the immune genes 29,59 oligoadenylate synthetase gene
3( OAS3) and sulfatase 1 (SULF1), and the epidermal dysplasia
verruciformis (EV)-associated EVER1 and EVER2 genes, TMC6
and TMC8 [8]. We now report our findings regarding the
remaining 18,310 SNPs (covering 1,113 genes) that were
genotyped on the same iSelect chip. These additional SNPs were
selected based on their a priori hypothesized relationship with a
wide range of cancers, but not specifically with HPV persistence
and cervical cancer. These genes were selected based on the
collective effort of numerous cancer researchers and include genes
in several immune, cytokine and inflammation response, DNA
replication and differentiation, macrophage differentiation, toll-
like receptor signaling, and T cell receptor signaling pathways, to
name a few, and presumably have lower prior probabilities of
association with cervical cancer than those studied in the report of
Wang et al. [8].
Results
Gene region-based associations
Table 1 shows results for 14 genes/regions with p,0.005 for
association with either disease (CIN3/cancer versus controls),
disease progression (CIN3/cancer versus HPV persistence), or
persistent infection (HPV persistence versus controls) (arranged by
p-value for disease associations). This analysis identified 9 gene
regions as statistically significantly associated with CIN3/cancer at
a p-value of #0.005 (PRDX3 p-value 0.00015; RPS19 p-value
0.00045; DDX1 p-value 0.0006; TELO2 p-value 0.0009; C1RL p-
value 0.00165; ILDR1 p-value 0.00285; THRAP4 p-value 0.0037;
GDF10 p-value 0.004; and GDF2 p-value 0.004). Two gene regions
were identified as statistically significantly associated with disease
progression at p-value of #0.005 (GC p-value 0.0004; and IL2RA
p-value 0.00115). In addition, 2 gene regions were identified as
significantly associated with type-specific HPV persistence (TYMS
p-value 0.0015; and EVPL p-value 0.0018). Of the genes identified
to be associated with CIN3/cancer RPS19 was also associated with
progression to CIN3/cancer (p-value 0.006). Similarly, of the
genes associated with CIN3/cancer, C1RL, GDF10, and GDF2
were also associated with persistence (p-values of 0.00875, 0.0423,
and 0.04080, respectively). Only two of the genes - PRDX3 and
RPS19, were notable with a FDR#0.2 comparing CIN3/cancers
to random controls. All gene-based results are shown in Table S1.
SNP-based associations
Six SNPs in 6 genes identified by the gene-based analysis were
significantly associated with CIN3/cancer, disease progression, or
persistent oncogenic HPV infection (Table 2) in SNP-based
analysis. The PRDX3 rs7082598 minor allele variants was
associated with statistically significant decreased risk of cervical
cancer compared to controls (ORCT/TT=0.41, 95%CI 0.30–0.58,
Ptrend,0.0001), and this protective effect was observed for both
progression (CIN3+ compared with HPV-persistence) and HPV-
persistence (persisters compared to controls) (ORCT/TT=0.58,
95%CI 0.40–0.83 Ptrend=0.008, and 0.71, 95%CI 0.52–0.97,
Ptrend=0.02 respectively). The RPS19 rs2305809 T allele was also
associated with statistically significant decreased risk of cervical
cancer (ORCT=0.66, 95%CI 0.48–0.91; ORTT=0.43, 95%CI
0.28–0.66, Ptrend=0.00007). Further examination by intermediate
steps showed that this effect remained for progression from
persistence to CIN3+ (ORCT=0.83, 95%CI 0.59–1.15;
ORTT=0.51, 95%CI 0.33–0.78, Ptrend=0.003). Lastly, the IL2RA
rs2476491 T variant was also associated with significantly
decreased risk of cervical cancer (ORAT/TT=0.69, 95%CI 0.51–
0.92, Ptrend=0.02). This association was strongest for progression
from HPV-persistence to CIN3+ (ORAT/TT=0.53, 95%CI 0.39–
0.71, Ptrend=0.00002).
Variants alleles in TELO2 rs4786772 (ORAG=1.54, 95%CI
1.14–2.09; ORGG=2.51, 95%CI 1.59-3.94, Ptrend=0.00002),
C1RL rs12227050 (ORAG/GG=2.85, 95%CI 1.71–4.74,
Ptrend=0.0001), and TYMS rs2342700 (ORCG=1.56, 95%CI
1.17–2.09; ORGG=2.18, 95%CI 1.30–3.64, Ptrend=0.0002) were
associated with significantly increased risk of cervical cancer
(Table 2). The increased risk of variants for TELO2 remained for
progression from persistence to CIN3+, while the increased risk for
C1RL and TYMS remained for persistence compared to random
controls.
We also carried out a single statistical analysis including all
SNPs, and found that the SNP RS7082598 (PRDX3 gene) retained
significance in this analysis when comparing CIN3+ vs. random
controls (multiple comparison adjusted p-value 0.011).
Discussion
In this analysis of genes and SNPs identified to be broadly
relevant for cancer etiology, but not specifically for cervical
carcinogenesis, we found 14 genes/regions that were significantly
associated with CIN3/cancer at p,.005. Two of these genes –
RPS19 and PRDX3 – were notable at a FDR#0.2. Replication of
these results is warranted to eliminate the role of chance finding.
Effects of putative genetic etiologic factors for cervical cancer
may be mapped to specific transition states from HPV infection of
the cervical transformation zone, progression of persistently
infected cervical cells to precancer and invasive cancer. In this
study we had the opportunity to investigate and identify genes
which may influence some of these stages of cervical carcinogen-
esis. We note that the protective effects observed for PRDX3 and
RPS19 SNPs remained for both disease progression (from HPV-
persistent infection to CIN3+) and for HPV-persistence.
Mutations of the ribosomal gene RPS19 have been associated
with Diamond-Blackfan anemia (DBA), which is a constitutional
erythroblastopenia characterized by absent or decreased erythroid
precursors, in a subset of patients. Patients with DBA have
increased risk of osteosarcoma. This association with DBA suggests
a possible extra-ribosomal function for this gene in erythropoietic
differentiation and proliferation, in addition to its ribosomal
function. In some primary colon carcinomas, higher expression
levels of this gene have been observed compared to matched
normal colon tissues [9]. PRDX3 is in the peroxiredoxin family
which encodes a protein with antioxidant function, is localized in
the mitochondrion, and may function to protect mitochondria
from oxidative stress. Sequence comparisons with recently cloned
mammalian homologues suggest that these genes consist of a
Host Genetics and Cervical Cancer Risk
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differentiation, and antioxidant functions [10,11]. Neither of these
genes has an obvious relationship to the known carcinogenic
processes that lead to cervical cancer.
There are several study limitations to be considered. We
combined the CIN3+ cases from the NHS cohort-based study with
the CIN3+ supplemental cases drawn from the community at the
same period for increased analytic power. There was a higher
proportion of CIN3 (a corollary of detection by screening in NHS
rather than symptoms) in the NHS cases than supplemental cases;
additionally supplemental cases were older, mainly because of the
larger proportion of cancers compared to the NHS cohort-based
cases where there were higher proportion of CIN3. Tests of
associations between NHS and supplemental populations for
94.2% (17,149/18,208) of the SNPs were not significant at 5%
level, importantly, all the SNPs associated with the two genes of
interest (PRDX3 and RPS19) were similarly distributed between
NHS and supplemental cases, justifying combining the two
cohorts. Additionally, this study was powered on a combined
end-point of CIN3 and cancer; 95.5% (17,394/18,208) of the
SNPs were not statistically different between CIN3 and cancer
cases. Importantly, none of SNPs associated with the two genes of
interest (PRDX3 and RPS19) were statistically significantly different
between CIN3 and cancers. Because SNPs were chosen as tagging
markers for genetic regions rather than function, the observed
associations with SNPs may be due to linkage disequilibrium with
other causal unmeasured SNPs. We were underpowered to
perform analyses restricted to carcinogenic HPV types due to
small sample size as only women enrolled in the original NHS had
HPV typing data. Future studies should therefore consider HPV
genotypes in analysis. We were also unable to evaluate genetic
factors associated with invasive cervical cancer separately. Future
studies with large number of cases will be required to address
whether certain genes are associated with transition from in situ to
invasive cervical cancer. Although we performed haplotype-based
analyses (defined by blocks of linkage disequilibrium); results were
generally consistent with the gene region- and SNP-based findings.
No new regions of interest were identified in haplotype analysis
using the sliding window approach of 3 SNPs. The genes
evaluated here were also not selected based on their previously
reported associations with cervical cancer, but by agnostic analysis,
encompassing a global effort to identify genes involved with a
range of infection and non-infection-related cancers.
In summary, these data suggest involvement of two genes,
RSP19 and PRDX3, or other SNPs in linkage disequilibrium, with
cervical cancer risk. Further investigation showed that they may be
involved in both the persistence and progression transition stages.
If replicated, these results may suggest a role for ribosomal
dysfunction, mitochondrial processes, and/or oxidative stress, or
as yet unknown function in cervical cancer pathogenesis.
Materials and Methods
Study population
Data are from the Guanacaste HPV Natural History Study
(NHS), a population-based cohort study in Guanacaste, Costa
Rica. Details of the cohort study methods [12,13] and of the sub-
population selected for genetic analyses [14,15] have been
reported elsewhere. Briefly, NHS is a population-based cohort of
10,049 women recruited over an 18-month period in 1993-4 and
followed for seven years. The primary objective of NHS was to
study the natural history of HPV infection and cervical
intraepithelial neoplasia (CIN). Cervical cells were available for
HPV DNA testing, and buffy coat specimens were available for
host gene polymorphism studies.
A host genetic sub-study was nested within NHS, as described
previously [14,15]. Briefly, individuals selected for the genetic sub-
study included: (i) all women in the cohort histologically confirmed
to have prevalent or incident CIN3 or cancer (CIN3+:
Table 1. Significance levels (p values) for gene regions with p#0.005, for either an association with (i) cervical precancer/cancer,
(ii) progression to cervical precancer/cancer, (iii) HPV persistence.
Chromosome # SNPs (i) (ii) (iii)
Gene CIN3+ (n=415) CIN3+ (n=415) HPV persistence (n=356)
vs. RC (n=425){ vs. HPV persistence (n=356) vs. RC (n=425)
PRDX3* 10q25-q26 11 0.00015 0.0744 0.16314
RPS19* 19q13.2 4 0.00045 0.00585 0.45823
DDX1 2p24 13 0.0006 0.69087 0.21284
TELO2 16p13.3 20 0.0009 0.17849 0.65932
C1RL 12p13.31 20 0.00165 0.14029 0.00875
ILDR1 3q13.33 11 0.00285 0.05830 0.88461
THRAP4 6 0.00370 0.80776 0.05615
GDF10 10q11.22 20 0.00400 0.13639 0.04230
GDF2 10q11.22 19 0.00400 0.12639 0.04080
TYMS 18p11.32 20 0.0055 0.30233 0.0015
EVPL 17q25 10 0.02055 0.08985 0.00180
GC 4q12-q13 19 0.0343 0.0004 0.00965
IL2RA 10p15-p14 44 0.24394 0.00115 0.44318
PIK3CA 3q26.3 11 0.91060 0.05145 0.00490
*FDR for both PRDX3 and RPS19=0.19.
{RC=random controls.
doi:10.1371/journal.pone.0033619.t001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e33619CIN3=140, cancer=45); (ii) all women in the cohort who at the
time of selection into the study had evidence of HPV persistence,
defined as women positive for the same HPV type (either
carcinogenic or not) at two consecutive visits at least 12 months
apart (n=432) (median length of observed persistence: 25
months); and (iii) a random selection of participants without
CIN3, or cancer from the baseline cohort (n=492). To increase
power for studies of host genetics, we conducted a supplemental
substudy that captured all CIN3 (n=240) and cancer cases
(n=87) who were not participants in NHS but were independently
diagnosed with CIN3 or cancer at Social Security clinics from the
same study area and during the same period in which NHS was
conducted [15]. The study was approved by both the US NCI and
Costa Rica Institutional Review Boards and all subjects signed
informed consent.
Laboratory Methods
DNA extraction from blood. DNA was extracted from buffy
coats with PureGene purification kits/Autopure protocol (Gentra
Systems) at SeraCare (Frederick, MD). For the supplemental cases
Table 2. Odds ratios and 95% confidence intervals for top-ranked SNPs (p#0.0001) with either an association with (i) cervical
precancer/cancer, (ii) progression to cervical precancer/cancer, or (iii) HPV persistence: (all models adjusted for age).
Gene rs # Random control HPV persistence CIN3/cancer CIN3/cancer CIN3/cancer vs HPV persistence
vs RC HPV persistence vs RC
N (%) N (%) N (%) OR (95% CI) OR (95% CI) OR (95% CI)
PRDX3 RS7082598
CC 288 (68) 266 (75) 346 (83) 1.0 (ref) 1.0 (ref) 1.0 (ref)
CT 127 (30) 87 (24) 64 (15) 0.41 (0.29–0.58) 0.55 (0.38–0.80) 0.74 (0.53–1.01)
TT 10 (2) 3 (1) 5 (1) 0.45 (0.15–1.35) 1.29 (0.29–5.65) 0.33 (0.09–1.20)
p-trend,0.00001 p-trend=0.008 p-trend=0.02
CT/TT 137 (32) 90 (25) 69 (17) 0.41 (0.30–0.58) 0.58 (0.40–0.83) 0.71 (0.52–0.97)
RPS19 RS2305809
CC 100 (24) 102 (29) 141 (34) 1.0 (ref) 1.0 (ref) 1.0 (ref)
CT 228 (54) 172 (48) 213 (51) 0.66 (0.48–0.91) 0.83 (0.59–1.15) 0.74 (0.53–1.05)
TT 97 (23) 82 (23) 60 (14) 0.43 (0.28–0.66) 0.51 (0.33–0.78) 0.83 (0.56–1.25)
p-trend=0.00007 p-trend=0.003 p-trend=0.34
CT/TT 325 (76) 254 (71) 273 (66) 0.59 (0.43–0.80) 0.72 (0.53–0.99) 0.77 (0.56–1.06)
Il2RA RS2476491
AA 262 (62) 196 (55) 289 (70) 1.0 (ref) 1.0 (ref) 1.0 (ref)
AT 147 (35) 135 (38) 114 (27) 0.69 (0.51–0.93) 0.56 (0.41–0.77) 1.22 (0.91–1.65)
TT 15 (4) 25 (7) 12 (3) 0.68 (0.31–1.5) 0.34 (0.16–0.70) 2.24 (1.15–4.37)
p-trend=0.02 p-trend=0.00002 p-trend=0.02
AT/TT 162 (38) 160 (45) 126 (30) 0.69 (0.51–0.92) 0.53 (0.39–0.71) 1.32 (0.99–1.76)
TELO2 RS4786772
AA 185 (44) 151 (42) 134 (32) 1.0 (ref) 1.0 (ref) 1.0 (ref)
AG 197 (46) 147 (41) 211 (51) 1.54 (1.14–2.09) 1.65 (1.19–2.27) 0.92 (0.68–1.24)
GG 42 (10) 58 (16) 69 (17) 2.51 (1.59–3.94) 1.40 (0.91–2.15) 1.68 (1.06–2.65)
p-trend=0.00002 p-trend=0.03 p-trend=0.13
AG/GG 239 (56) 205 (58) 280 (68) 1.71 (1.28–2.28) 1.57 (1.16–2.13) 1.05 (0.79–1.39)
C1RL RS12227050
GG 402 (95) 310 (87) 357 (86) 1.0 (ref) 1.0 (ref) 1.0 (ref)
AG 22 (5) 45 (13) 57 (14) 2.91 (1.73–4.89) 1.06 (0.69–1.62) 2.73 (1.60–4.65)
AA 1 (0.2) 1 (0.3) 1 (0.2) 1.37 (0.08–22.18) 0.77 (0.05–12.91) 1.36 (0.08–21.92)
p-trend=0.0001 p-trend=0.85 p-trend=0.0004
AG/AA 23 (5) 46 (13) 58 (14) 2.85 (1.71–4.74) 1.05 (0.69–1.61) 2.67 (1.58–4.51)
TYMS RS2342700
CC 227 (53) 145 (41) 169 (41) 1.0 (ref) 1.0 (ref) 1.0 (ref)
CG 169 (40) 164 (46) 199 (48) 1.56 (1.17–2.09) 1.06 (0.78–1.44) 1.53 (1.13–2.06)
GG 29 (7) 47 (13) 46 (11) 2.18 (1.30–3.64) 0.87 (0.54–1.40) 2.57 (1.54–4.27)
p-trend=0.0002 p-trend=0.78 p-trend=0.00005
CG/GG 198 (47) 211 (59) 245 (59) 1.65 (1.25–2.18) 1.02 (0.76–1.37) 1.68 (1.26–2.23)
doi:10.1371/journal.pone.0033619.t002
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using the same kit.
HPV testing. PCR-based HPV DNA testing was conducted
using the L1 MY09/MY11 consensus primer methods [12,16,17]
on cervical cells stored in specimen transport media (Qiagen,
USA) from the natural history study only. Because cervical cells
were not obtained from the supplemental cases, HPV results are
restricted to women within the original cohort.
Host genotyping. A panel was designed as part of an effort of
numerous investigators based on their expertise in specific cancers.
Genotyping of tag SNPs from 990 candidate gene regions
hypothesized to be involved in wide number of cancers such as
colon, osteosarcoma, esophageal and stomach, biliary, Fanconi
anemia, bladder, breast and other cancers, was conducted at the
NCI Core Genotyping Facility (Advanced Technology Center,
Gaithersburg, MD; http://snp500cancer.nci.nih.gov) [18] using a
custom-designed iSelect Infinium assay (Illumina, www.illumina.
com). The Infinium included a total of 27,904 tag SNPs. Tag
SNPs of the genes were chosen from the designable set of common
SNPs (minor allele frequency (MAF.5%) genotyped using the all
3 HapMap populations for tagging dependent on the population
of interest for the investigator suggesting the candidate gene (Data
Release 20/Phase II, NCBI Build 36.1 assembly, dbSNPb126)
using the software Tagzilla (http://tagzilla.nci.nih.gov/), which
implements a tagging algorithm based on the pairwise binning
method of Carlson et al. [19]. For each original target gene, SNPs
within the region spanning 20 kb 59 of the start of transcription
(exon 1) to 10 kb 39 of the end of the last exon were grouped using
a binning threshold of r
2.0.8 to define a gene region. When there
were multiple transcripts available for genes, only the primary
transcript was assessed.
Quality control (QC). Tag SNPs that failed manufacturing
(ordered but failed assay development), failed validation (no
amplification or clustering) and assays that had less than 80%
completion or 80% concordance with the 270 HapMap samples
used for validation were excluded (n=269). SNPs with low
completion rate (,90% of samples) were further excluded
(N=482). SNPs with QC discordance among our 100 QC
duplicates and among HapMap samples ,98% were excluded
(n=1,703). We also excluded samples with a completion rate
,90% (n=7). Hardy–Weinberg equilibrium was evaluated
among controls, 49 SNPs showed evidence of deviation from
Hardy–Weinberg proportions. Our QC data did not suggest any
obvious genotyping error in these 49, and their results are
therefore presented. Of the 20,764 SNPs, 18,310 SNPs from 1113
genes were included in our present analysis.
Final analytic population. We evaluated a total of 416
women diagnosed with CIN3 or cancer, 356 women with HPV
persistent infection, and 425 random controls for whom validated
genotyping results were obtained.
Statistical Analysis
Gene-based analyses. We obtained a gene-level summary of
association using the adaptive combination of p-values [20], which
combines gene-level association evidence through adaptive rank
truncated product method. We highlight results of the genes that
were significant at p-value,0.005. Because some of our results
could be due to false-positive findings, we calculated the false
discovery rate (FDR) among associations considered significant
using the method of Benjamini and Hochberg [21] to the gene
region-based tests
19. We considered an FDR value of ,0.2 as
notable.
SNP-based associations. We calculated odds ratios (OR)
and 95% confidence intervals (95% CI) for each genotype with
each disease outcome (CIN3/cancers vs. random controls; HPV-
persistence vs. CIN3/cancers; HPV-persistence vs. random
controls), using the homozygous wild type (WT) genotype as the
referent group. We first compared CIN3/cancer cases to random
controls. We further evaluated their associations for HPV
progression and/or persistence by comparing: the group of
CIN3/cancer cases (n=415) to HPV persisters (n=356) for
evaluation of SNPs relevant to progression and (ii) HPV persisters
(n=356) to random controls (n=425) for evaluating SNPs
relevant to persistence. We note that persistence does not always
precede CIN3, as it may be a result of a CIN3 lesion.
We conducted both crude and age-adjusted (,30, 30–49, 50+
years) analyses. For each outcome, we calculated the Ptrend based
on the three-level ordinal variable (0, 1, and 2) of homozygote
wildtype, heterozygote, and homozygote variant in a logistic
regression model. Because of the small cell size examining some of
the SNPs (less than 5%), we also show combined effect of
heterozygous and homozygous variant genotypes; thus, results of
the two-level models are discussed. All logistic regression models
were unconditional and conducted using SAS version 9.1 (SAS
Institute, Cary, NC).
Supporting Information
Table S1 Results for all gene based tests for either an association
with (i) cervical precancer/cancer, (ii) progression to cervical
precancer/cancer, or (iii) HPV persistence.
(XLS)
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